X0306 4 2023-02-17 0 0001348911 KalVista Pharmaceuticals, Inc. KALV 0001691090 Feener Edward P. C/O KALVISTA PHARMACEUTICALS, INC. 55 CAMBRIDGE PARKWAY, SUITE 901E CAMBRIDGE MA 02142 0 1 0 0 Chief Scientific Officer Common Stock 2023-02-17 4 M 0 4204 A 66580 D Common Stock 2023-02-17 4 S 0 2228 7.66 D 64352 D Performance Restricted Stock Unit 2023-02-17 4 M 0 2430 0.00 D Common Stock 2430 0 D Restricted Stock Unit 2023-02-17 4 M 0 1774 0.00 D Common Stock 1774 23059 D Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Shares earned upon the vesting of a percentage of the performance restricted stock units ("PRSUs") granted to the Reporting Person on January 11, 2023. Each PRSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of Performance Data and Enrollment Metrics goals ("Performance Metrics"). 1/12th of the total number of shares subject to the PSRU shall vest on each quarterly anniversary of the Vesting Commencement Date of November 17, 2022, upon Performance Metrics achieved, subject to continued service through each vesting date. 1/16th of the total RSUs subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, subject to continued service through each vesting date. /s/ Benjamin L. Palleiko, Attorney-in-Fact 2023-02-23